Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 11/20 | 0.64 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 5/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28708481 | 1.00 | PTGER4 (0.64) | PTGER4PTGER2ACACBACACAPHGDH | |
| SCHEMBL28690240 | 0.93 | PTGER4 (0.74) | PTGER4PTGER2PHGDH | |
| SCHEMBL24861863 | 0.93 | PTGER4 (0.74) | PTGER4PTGER2PHGDH | |
| SCHEMBL24861966 | 0.92 | PTGER4 (0.62) | PTGER4PTGER2ACACBACACAPHGDH | |
| SCHEMBL26416723 | 0.91 | PTGER4 (0.69) | PTGER4PTGER2ACACBACACAPDE2A | |
| SCHEMBL26416646 | 0.89 | PTGER4 (0.66) | PTGER4PTGER2PHGDHPDE2ALMNA | |
| SCHEMBL28702062 | 0.89 | PTGER4 (0.71) | PTGER4PTGER2ACACBACACAPHGDH | |
| SCHEMBL26418497 | 0.89 | PTGER4 (0.71) | PTGER4PTGER2ACACBACACAPHGDH | |
| SCHEMBL30331095 | 0.89 | PTGER4 (0.71) | PTGER4PTGER2ACACBACACAPHGDH | |
| SCHEMBL28708484 | 0.87 | PTGER4 (0.61) | PTGER4PTGER2PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4116291-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCERS AND INFLAMMATIONS | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-01-11 | — | — | EP | disclosed |
| EP-4116291-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCERS AND INFLAMMATIONS | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-01-11 | — | — | EP | disclosed |
| CN-113354585-A | Synthesis of novel EP4 antagonists and their use in cancer and inflammation | 湖北生物医药产业技术研究院有限公司 | 2021-09-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | PTGER4, PTGER3, PTGER2 | PTGER4 1/4885PTGER2 3/4885ACACB 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.